glp-1 slows gastric emptying Nearly half of users discontinue within a year. Not because the medication “failed.” Often because the digestive adjustment wasn't supported. GLP-1s intentionally slow emptying. That shift changes motility patterns. If Gastroparesis: Symptoms, Causes, Diagnosis &

Declarations Conflict of interest Bartlomiej Kwiek reported serving as a clinical study investigator for AbbVie, Amgen inc, Arcutis Biotherapeuthics, Almirall, Aslan, Bristol-Myers Squibb, Celdex Therapeutics, Celltrion, Dermira, Galderma, Glenmark, Incyte, Janssen Pharmaceuticals, LEO Pharma, Novartis, Pfizer, Regeneron, Samsung

Unlike hGH, which carries broader systemic effects and risks associated with elevated IGF-1 levels, AOD9604 appears to selectively promote fat metabolism without triggering growth-related side effects, suggesting its potential as a safer therapeutic candidate for obesity and metabolic disorders [2]

Stable gastric pentadecapeptide BPC 157: novel mediator of Roberts cytoprotection and adaptive cytoprotection. Current Pharmaceutical Design, 20(7), 11261135

Butyrate helps maintain healthy neuroinflammatory responses through several mechanisms

NICE guidance (NG28) recommends: HbA1c monitoring every 36 months until stable, then 6-monthly Renal function tests at least annually (more frequently if pre-existing kidney disease) Weight and BMI tracking to assess treatment response Blood pressure monitoring , as weight loss may allow reduction in antihypertensive medications Appropriate retinopathy screening for patients with diabetes, particularly those with pre-existing retinopathy taking semaglutide Communication with your healthcare team is vital

But if you have ever stared at a vial, a syringe, and an alcohol swab wondering where to even begin, you are not alone